RSLS logo

ReShape Lifesciences (RSLS) Cash From Operations

Annual CFO

-$16.96 M
+$4.94 M+22.56%

December 31, 2023


Summary


Performance

RSLS Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRSLScash flowmetrics:

Quarterly CFO

-$311.00 K
+$1.05 M+77.08%

September 30, 2024


Summary


Performance

RSLS Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRSLScash flowmetrics:

TTM CFO

-$6.20 M
+$2.47 M+28.49%

September 30, 2024


Summary


Performance

RSLS TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRSLScash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

RSLS Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+22.6%+88.8%+64.3%
3 y3 years-98.4%+96.0%+54.8%
5 y5 years+38.3%+68.1%+23.6%

RSLS Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-10.3%+22.6%at high+95.8%at high+75.2%
5 y5-year-98.4%+22.6%at high+96.0%at high+75.2%
alltimeall time-98.4%+49.6%at high+96.7%at high+81.6%

ReShape Lifesciences Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$311.00 K(-77.1%)
-$6.20 M(-28.5%)
Jun 2024
-
-$1.36 M(-34.5%)
-$8.67 M(-38.0%)
Mar 2024
-
-$2.07 M(-15.7%)
-$13.97 M(-17.6%)
Dec 2023
-$16.96 M(-22.6%)
-$2.46 M(-11.6%)
-$16.96 M(-2.1%)
Sep 2023
-
-$2.78 M(-58.3%)
-$17.33 M(-12.6%)
Jun 2023
-
-$6.66 M(+31.6%)
-$19.82 M(+1.2%)
Mar 2023
-
-$5.06 M(+78.9%)
-$19.59 M(-10.6%)
Dec 2022
-$21.90 M(+42.5%)
-$2.83 M(-46.3%)
-$21.90 M(-2.7%)
Sep 2022
-
-$5.27 M(-17.9%)
-$22.50 M(-10.1%)
Jun 2022
-
-$6.42 M(-13.0%)
-$25.03 M(+20.4%)
Mar 2022
-
-$7.38 M(+115.4%)
-$20.79 M(+35.2%)
Dec 2021
-$15.38 M(+79.8%)
-$3.43 M(-56.1%)
-$15.38 M(+12.1%)
Sep 2021
-
-$7.80 M(+256.5%)
-$13.71 M(+99.1%)
Jun 2021
-
-$2.19 M(+11.6%)
-$6.89 M(-5.2%)
Mar 2021
-
-$1.96 M(+11.3%)
-$7.27 M(-15.0%)
Dec 2020
-$8.55 M(-39.8%)
-$1.76 M(+80.5%)
-$8.55 M(+5.4%)
Sep 2020
-
-$976.00 K(-62.0%)
-$8.11 M(-28.9%)
Jun 2020
-
-$2.57 M(-20.9%)
-$11.41 M(-2.8%)
Mar 2020
-
-$3.25 M(+145.6%)
-$11.75 M(-17.3%)
Dec 2019
-$14.20 M(-48.3%)
-$1.32 M(-69.1%)
-$14.20 M(-28.9%)
Sep 2019
-
-$4.28 M(+47.6%)
-$19.97 M(-1.5%)
Jun 2019
-
-$2.90 M(-49.1%)
-$20.27 M(-15.1%)
Mar 2019
-
-$5.70 M(-19.6%)
-$23.87 M(-13.2%)
Dec 2018
-$27.49 M(+11.8%)
-$7.09 M(+54.9%)
-$27.49 M(-6.0%)
Sep 2018
-
-$4.58 M(-29.6%)
-$29.26 M(-3.5%)
Jun 2018
-
-$6.50 M(-30.2%)
-$30.33 M(+2.9%)
Mar 2018
-
-$9.32 M(+5.2%)
-$29.47 M(+19.8%)
Dec 2017
-$24.59 M(+19.0%)
-$8.86 M(+57.0%)
-$24.59 M(+27.7%)
Sep 2017
-
-$5.64 M(-0.1%)
-$19.26 M(+5.5%)
Jun 2017
-
-$5.65 M(+27.1%)
-$18.25 M(+0.3%)
Mar 2017
-
-$4.44 M(+25.7%)
-$18.20 M(-11.9%)
Dec 2016
-$20.66 M(-8.6%)
-$3.53 M(-23.7%)
-$20.66 M(-8.1%)
Sep 2016
-
-$4.63 M(-17.1%)
-$22.49 M(-5.9%)
Jun 2016
-
-$5.59 M(-19.0%)
-$23.89 M(+0.0%)
Mar 2016
-
-$6.90 M(+28.6%)
-$23.88 M(+5.7%)
DateAnnualQuarterlyTTM
Dec 2015
-$22.61 M(+16.6%)
-$5.36 M(-11.1%)
-$22.61 M(+4.3%)
Sep 2015
-
-$6.03 M(+8.0%)
-$21.67 M(+8.3%)
Jun 2015
-
-$5.59 M(-0.6%)
-$20.02 M(+3.2%)
Mar 2015
-
-$5.62 M(+26.9%)
-$19.40 M(+0.1%)
Dec 2014
-$19.38 M(+5.2%)
-$4.43 M(+1.1%)
-$19.38 M(+0.6%)
Sep 2014
-
-$4.38 M(-11.9%)
-$19.27 M(+2.6%)
Jun 2014
-
-$4.97 M(-11.2%)
-$18.78 M(-1.5%)
Mar 2014
-
-$5.60 M(+29.9%)
-$19.05 M(+3.4%)
Dec 2013
-$18.43 M(-18.0%)
-$4.31 M(+10.9%)
-$18.43 M(-6.0%)
Sep 2013
-
-$3.89 M(-26.0%)
-$19.60 M(-2.9%)
Jun 2013
-
-$5.25 M(+5.6%)
-$20.18 M(+0.5%)
Mar 2013
-
-$4.97 M(-9.3%)
-$20.08 M(-10.7%)
Dec 2012
-$22.48 M(+12.8%)
-$5.49 M(+22.6%)
-$22.48 M(+0.3%)
Sep 2012
-
-$4.47 M(-13.1%)
-$22.41 M(-3.1%)
Jun 2012
-
-$5.15 M(-30.2%)
-$23.12 M(+2.7%)
Mar 2012
-
-$7.37 M(+36.2%)
-$22.51 M(+12.9%)
Dec 2011
-$19.94 M(+45.9%)
-$5.41 M(+4.3%)
-$19.94 M(+10.4%)
Sep 2011
-
-$5.19 M(+14.5%)
-$18.06 M(+13.9%)
Jun 2011
-
-$4.53 M(-5.5%)
-$15.85 M(+6.9%)
Mar 2011
-
-$4.80 M(+35.7%)
-$14.83 M(+8.5%)
Dec 2010
-$13.66 M(-44.6%)
-$3.54 M(+18.6%)
-$13.66 M(-21.3%)
Sep 2010
-
-$2.98 M(-15.1%)
-$17.37 M(-14.7%)
Jun 2010
-
-$3.51 M(-3.4%)
-$20.35 M(-8.1%)
Mar 2010
-
-$3.63 M(-49.8%)
-$22.14 M(-10.2%)
Dec 2009
-$24.66 M(-26.8%)
-$7.24 M(+21.4%)
-$24.66 M(-8.4%)
Sep 2009
-
-$5.97 M(+12.7%)
-$26.93 M(-8.4%)
Jun 2009
-
-$5.30 M(-14.0%)
-$29.38 M(-8.6%)
Mar 2009
-
-$6.16 M(-35.3%)
-$32.15 M(-4.5%)
Dec 2008
-$33.67 M(+44.1%)
-$9.51 M(+12.9%)
-$33.67 M(+39.4%)
Sep 2008
-
-$8.42 M(+4.5%)
-$24.16 M(+53.5%)
Jun 2008
-
-$8.06 M(+5.0%)
-$15.74 M(+105.0%)
Mar 2008
-
-$7.68 M
-$7.68 M
Dec 2007
-$23.37 M(+44.0%)
-
-
Dec 2006
-$16.23 M(+57.9%)
-
-
Dec 2005
-$10.28 M
-
-

FAQ

  • What is ReShape Lifesciences annual cash flow from operations?
  • What is the all time high annual CFO for ReShape Lifesciences?
  • What is ReShape Lifesciences annual CFO year-on-year change?
  • What is ReShape Lifesciences quarterly cash flow from operations?
  • What is the all time high quarterly CFO for ReShape Lifesciences?
  • What is ReShape Lifesciences quarterly CFO year-on-year change?
  • What is ReShape Lifesciences TTM cash flow from operations?
  • What is the all time high TTM CFO for ReShape Lifesciences?
  • What is ReShape Lifesciences TTM CFO year-on-year change?

What is ReShape Lifesciences annual cash flow from operations?

The current annual CFO of RSLS is -$16.96 M

What is the all time high annual CFO for ReShape Lifesciences?

ReShape Lifesciences all-time high annual cash flow from operations is -$8.55 M

What is ReShape Lifesciences annual CFO year-on-year change?

Over the past year, RSLS annual cash flow from operations has changed by +$4.94 M (+22.56%)

What is ReShape Lifesciences quarterly cash flow from operations?

The current quarterly CFO of RSLS is -$311.00 K

What is the all time high quarterly CFO for ReShape Lifesciences?

ReShape Lifesciences all-time high quarterly cash flow from operations is -$311.00 K

What is ReShape Lifesciences quarterly CFO year-on-year change?

Over the past year, RSLS quarterly cash flow from operations has changed by +$2.47 M (+88.81%)

What is ReShape Lifesciences TTM cash flow from operations?

The current TTM CFO of RSLS is -$6.20 M

What is the all time high TTM CFO for ReShape Lifesciences?

ReShape Lifesciences all-time high TTM cash flow from operations is -$6.20 M

What is ReShape Lifesciences TTM CFO year-on-year change?

Over the past year, RSLS TTM cash flow from operations has changed by +$11.13 M (+64.25%)